Radiographic progression and remission rates in early rheumatoid arthritis: MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial

Merete Lund Hetland, Kristian Stengaard-Pedersen, Peter Junker, Mikkel Østergaard, Bo J Ejbjerg, Søren Jacobsen, Tine Lottenburger, Ib Hansen, Ulrik Tarp, Lis Abildgaard Andersen, Anders Svendsen, Jens K Pedersen, Ulrik Birk Lauridsen, Torkell Juulsgaad Ellingsen, Hanne Lindegaard, Jan Pødenphant, Aage Vestergaard, Anne Grethe Jurik, Kim Hørslev-Petersen, CIMESTRA study group

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

At 5 years' follow-up of early (
Original languageEnglish
JournalAnnals of the Rheumatic Diseases
Volume69
Issue number10
Pages (from-to)1789-95
Number of pages7
ISSN0003-4967
DOIs
Publication statusPublished - 1. Oct 2010

Keywords

  • Adult
  • Aged
  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Autoantibodies
  • Biological Markers
  • Bone Marrow Diseases
  • Cyclosporine
  • Disease Progression
  • Drug Therapy, Combination
  • Edema
  • Epidemiologic Methods
  • Female
  • Humans
  • Immunosuppressive Agents
  • Magnetic Resonance Imaging
  • Male
  • Methotrexate
  • Middle Aged
  • Peptides, Cyclic
  • Prognosis
  • Remission Induction

Fingerprint

Dive into the research topics of 'Radiographic progression and remission rates in early rheumatoid arthritis: MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial'. Together they form a unique fingerprint.

Cite this